Xin Lang Cai Jing·2025-11-20 03:32Group 1 - The core point of the news is that Jingxin Pharmaceutical experienced a stock price increase of 5.22%, reaching 21.36 CNY per share, with a trading volume of 276 million CNY and a turnover rate of 1.84%, resulting in a total market capitalization of 18.392 billion CNY [1] - Jingxin Pharmaceutical, established on February 13, 1999, and listed on July 15, 2004, is located in Xinchang County, Zhejiang Province. The company specializes in the research, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices. The revenue composition is 82.46% from pharmaceutical manufacturing and 17.54% from medical devices [1] Group 2 - From the perspective of major fund holdings, one fund under Guotai Haitong Asset Management has a significant position in Jingxin Pharmaceutical. The Guotai Haitong Innovative Pharmaceutical Mixed Fund A (014157) held 390,000 shares in the third quarter, accounting for 5.47% of the fund's net value, making it the third-largest holding. The estimated floating profit today is approximately 413,400 CNY [2] - The Guotai Haitong Innovative Pharmaceutical Mixed Fund A (014157) was established on December 23, 2021, with a latest scale of 1.05 billion CNY. Year-to-date returns are 17.96%, ranking 4386 out of 8136 in its category; the one-year return is 16.49%, ranking 4438 out of 8055; and since inception, it has a loss of 5.15% [2] - The fund manager, Li Zibo, has been in the position for 3 years and 334 days, with the total asset size of the fund at 3.067 billion CNY. The best fund return during his tenure is 34.23%, while the worst is -4.41% [2]